Education
About Us
Working with TipRanks
Follow Us
Genelux Corp. (GNLX)
:GNLX
GNLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $5.89
Previous CloseN/A
Volume23.79K
Average Volume (3M)188.29K
Market Cap
$81.49M
Enterprise Value$52.93M
Total Cash (Recent Filing)$2.84M
Total Debt (Recent Filing)$6.32M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 08, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding37,728,140
10 Day Avg. Volume284,988
30 Day Avg. Volume188,286
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16966.88
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.62K
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$18.25Price Target Upside744.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive initial data from the ongoing study evaluating Olvi-Vec with platinum chemotherapy in small cell lung cancer patients shows promising results.
Financial StabilityThe equity financing of $10.5 million combined with existing cash provides financial runway into 2026, supporting ongoing and future trials.
Regulatory MilestonesThe FDA recommended adding an interim overall survival analysis to the progression-free survival primary endpoint in the ovarian cancer trial, indicating potential for full approval.
Bears Say
Future ExpensesEstimates for 2025 operating expenses are $41.3M, which assumes increased spending due to ongoing clinical trials including the Phase 3 ovarian cancer study and Phase 2 recurrent NSCLC study.
Net LossGenelux reported a net loss of $6.5M, but maintains $35.1M in cash, providing financial runway into 1Q26.
Operating ExpensesIn 4Q24, the company reported operating expenses of $9.7M, which was higher than 3Q24, likely associated with costs related to initiating to recurrent NSCLC study in the US.
---
Ownership Overview
13.04% Insiders
4.27% Mutual Funds
5.29% Other Institutional Investors
73.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.60 and its highest was $5.88 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $81.49M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is May 08, 2025 which is in 28 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Mar 28, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.064.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.24.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 37,728,140 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went down -12.338%.
Which hedge fund is a major shareholder of Genelux Corp.?
Among the largest hedge funds holding Genelux Corp.’s share is Highbridge Capital Management LLC. It holds Genelux Corp.’s shares valued at 0.
---
Genelux Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.25 (744.91% Upside)
$18.25 (744.91% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-55.46%
12-Months-Change
Fundamentals
Return on Equity
-130.58%
Trailing 12-Months
Asset Growth
24.46%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
---
GNLX Stock 12 Month Forecast
Average Price Target
$18.25
▲(744.91% Upside)
Technical Analysis
Precigen
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Replimune Group
―
Best Analysts Covering GNLX
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-41.47%
reiterated a buy rating 2 days ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -41.47% per trade.
---